Cardiac Glycosides sales in Canada are on a consistent decline from 2024 onward, with projected revenues decreasing slightly each year, showing a downward trend in the demand or usage. In 2023, sales stood at 10.5 million USD. Forecasts show an average annual decrease of approximately 1.7% from 2024 to 2028. The consistent decline over these years indicates a negative Compound Annual Growth Rate (CAGR). The sales trajectory appears to indicate shrinking interest or alternative solutions gaining traction over this period.
Future trends to watch include the impact of emerging cardiac technologies, possible new entrants or competitors in heart health solutions, and any shifts toward alternative therapies that might further affect Cardiac Glycosides demand in Canada.
